Celloram was awarded a $0.2M grant from the U.S. Department of Defense to improve post-trauma induced osteoarthritis. Osteoarthritis is a leading cause of mobility-related disability and is usually induced by the gradual wearing-down of joint cartilage over time. Post-trauma induced osteoarthritis, or PTOA, is a subtype of osteoarthritis that develops after joint injury and therefore disproportionality effects a young population.
Many PTOA cases recover within 6 months, but some cases can develop into chronic disease. The activation of inflammatory mechanisms is thought to play an important role in the progression of acute to chronic disease, so early interventions are of interest. Celloram hopes that by applying its innovative cell therapy technologies that work with the power of the immune system, we can develop early-intervention therapies to treat this debilitating chronic condition.